ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2019

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

M H Kulke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.